New York, Feb 27, 2026, 06:19 EST — Premarket
- Humana bounced 6.1% last session, shaking off several days of losses and pulling away from its recent lows
- Industry growth in Medicare Advantage has slowed, a new enrollment report shows, but Humana picked up the lion’s share of gains.
- Attention turns to U.S. payment-rate calls and imminent company updates as the next catalysts for HUM.
Humana Inc jumped 6.1% Thursday, finishing the day at $186.83 after moving within a range of $177.75 to $187.44. Even with the rally, shares remain down about 41% from their 52-week peak, but are sitting roughly 10% above the 52-week low.
This is key right now: Humana’s core business is Medicare Advantage — those private plans for Medicare recipients. Shifts in enrollment and changes to federal per-member payments have a direct impact on profit outlooks, and lately, the sector’s been reacting to every policy headline.
Medicare Advantage enrollment climbed by roughly 900,000 for the 2026 plan year, bumping total membership to 35.4 million, according to a new report from HealthScape Advisors and Chartis. Growth edged lower, to 2.5%. Most of those new sign-ups went to Humana, with UnitedHealthcare and Aetna cutting back. Alexis Levy, who co-authored the report, described the pace as “sustained moderation,” while Chartis’ Nick Herro said plans are leaning harder into “targeted segments” like Special Needs Plans. PR Newswire
Special Needs Plans—SNPs—are a type of Medicare Advantage plan tailored for those with specific chronic conditions or for people who are dual-eligible for Medicaid. These plans often see less member turnover, yet they typically come with steeper medical requirements, so cost trends remain a key focus.
Barclays slashed its price target on Humana, dropping it to $176 from $245, while maintaining an Equal Weight rating. The bank cited a more “incrementally cautious” stance toward Humana’s projection that individual Medicare Advantage margins will double. TipRanks
Sanjay K. Shetty, who runs Humana’s CenterWell division, picked up 810 shares at $185.205 each on Feb. 23, boosting his direct stake to 11,657 shares, according to a separate regulatory filing.
Humana has spent this month working to manage the fallout after projecting 2026 earnings that trail Wall Street’s expectations, a shortfall blamed on weaker Medicare Advantage “star ratings.” Those government quality scores directly affect bonus payments. CEO Jim Rechtin cited the need to adjust for shifting U.S. “fiscal dynamics.” Morningstar analyst Julie Utterback warned that picking up the pace on membership growth may “further strain margins.” Reuters
Policy risk remains the wild card. CMS has floated a net average payment bump of just 0.09% for 2027, with the final rate reveal expected by April 6, following the Feb. 25 close of the comment period. Also on the table: tougher rules for “risk adjustment,” the formula used to adjust payments depending on members’ health status. The agency aims to put stricter limits on using diagnoses from unlinked chart reviews. CMS
The rebound won’t stick if medical costs stay elevated or if new sign-ups end up weighted toward higher-expense members, especially with rate hikes looming into 2027. If margin recovery drags out beyond what’s been pledged, expect the stock to face the same pressure it felt earlier this month.
Investors now turn to see if Thursday’s bounce can stick at the open. They’re also eyeing any fresh target changes from brokers reacting to the enrollment numbers. Shifts in other names with sizable Medicare Advantage exposure often ripple through the group.
Humana’s CEO Jim Rechtin and CFO Celeste Mellet are slated to appear at the Leerink Partners Global Healthcare Conference on March 10, speaking at 10:40 a.m. Eastern. Investors get an early look at management’s tone ahead of the crucial April 6 government rate deadline.
